Canaccord Reiterates Buy Rating on Biodesix (BDSX)

Mon, 02 Mar 2026 04:57:06 +0000

Canaccord analyst Kyle Mikson reiterated a Buy rating and $20.00 price target on Biodesix (NASDAQ: BDSX).

The analyst comments "We reiterate our BUY rating on Biodesix (BDSX) shares and maintain our price target at $20. After the market close on Thursday, February 26, the company reported 4Q25 results that were in line with its preliminary announcement on 1/12. BDSX delivered strong performance driven by higher test volumes and improved average revenue per test. Importantly, Biodesix achieved positive adjusted EBITDA of $0.5 million in 4Q25, supported by +41% y/y revenue growth and overall operating leverage. The company provided initial 2026 revenue guidance

StreetInsider.com News Articles

Canaccord Reiterates Buy Rating on Biodesix (BDSX)